Is the antidepressive effect of second-generation antidepressants a myth?

Psychological Medicine

Volumn 40, Issue 2, 2010, Pages 181-186

  Bech, P ^a  

^a FREDERIKSBORG GENERAL HOSPITAL   (Denmark)

Author keywords

Antidepressive effect; Doseresponse relationship; Effect size; HAMD6; Relapse prevention

Indexed keywords

ANTIDEPRESSANT AGENT;

ANXIETY DISORDER; DRUG ADMINISTRATION; EDITORIAL; FACTORIAL ANALYSIS; GUILT; HOSPITALIZATION; HUMAN; INTERPERSONAL COMMUNICATION; MAJOR DEPRESSION; PSYCHOLOGICAL ASPECT; PSYCHOMOTOR DISORDER; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION SCHEDULE; FACTOR ANALYSIS, STATISTICAL; GUILT; HUMANS; PSYCHOMOTOR DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRUTH DISCLOSURE;

EID: 76649143740     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291709006102     Document Type: Review

References (53)

1. Angst J (2007). Psychiatric diagnoses: the weak component of modern research. World Psychiatry 6, 94-95.
2. Bech P (2001). Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. International Journal of Neuropsychopharmacology 4, 337-345.
3. Bech P (2007). Dose-response relationship of Pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry 40, 163-168.
4. Bech P (2009). Fifty years with the Hamilton scales for anxiety and depression. Psychotherapy and Psychosomatics 78, 202-211.
5. Bech P, Allerup P, Gram LF, Reisby N, Rosenberg R, Jacobsen O, Nagy A (1981). The Hamilton Depression Scale. Evaluation of objectivity using logistic models. Acta Psychiatrica Scandinavica 63, 290-299.
6. Bech P, Allerup P, Reisby N, Gram LF (1984). Assessment of symptom change from improvement curves on the Hamilton Depression Scale in trials with antidepressants. Psychopharmacology 84, 276-281.
7. Bech P, Cialdella P, Haugh M, Birkett MA, Hours A, Boissel JP, Tollefson GD (2000). A meta-analysis of randomised controlled trials of fluoxetine versus placebo and tricyclic antidepressants in the short-term treatment of major depression. British Journal of Psychiatry 176, 421-428.
8. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG (1975). Quantitative rating of depressive states. Acta Psychiatrica Scandinavica 51, 161-170.
9. Bech P, Kajdasz DK, Porsdal V (2006). Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology 188, 273-280.
10. Bech P, Tanghøj P, Andersen HF, Overø K (2002). Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology 163, 20-25.
11. Bech P, Tanghøj P, Cialdella P, Friis Andersen H, Pedersen AG (2004). Escitalopram dosee-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. International Journal of Neuropsychopharmacology 7, 283-290.
12. Beck AT (1973). The Diagnosis and Management of Depression. University of Pennsylvania Press: Philadelphia.
13. Bent-Hansen J, Lunde M, Klysner R, Andersen M, Tanghøj P, Solstad K, Bech P (2003). The validity of the depression rating scales in discriminating between citalopram and placebo in depression recurrence in the maintenance therapy of elderly unipolar patients with major depression. Pharmacopsychiatry 6, 313-316.
14. Bollini P, Pampallona S, Tbaldi G, Kupelnick B, Munizza C (1999). Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. British Journal of Psychiatry 174, 297-303.
15. Boyer P, Montgomery S, Lepola U (2008). Efficacy, safety and tolerability of fixed-dose desvenlafaxine 50 mg and 100 mg/day for major depression in a placebo-controlled trial. International Clinical Psychopharmacology 23, 248-253.
16. Cohen J (1976). Statistical Power Analysis for the Behavioural Sciences. Lawrence Erlbaum, New York.
17. Detke MJ, Wiltse CG, Mallinckrodt CH, Mc Namara RK, Demitrack MA, Bitter I (2004). Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo-and paroxetine-controlled trial. European Neuropsychopharmacology 14, 457-470.
18. Entsuah R, Shaffer M, Zhang J (2002). A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects. Journal of Psychiatric Research 36, 437-448.
19. European Union (1994). Guidelines on psychotropic drugs: antidepressant medical products. European Neuropsychopharmacology 4, 62-65.
20. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 61, 653-661.
21. Hamilton M (1967). Development of a rating scale for primary depressive illness. British Journal of social and Clinical Psychology 6, 278-296.
22. Hamilton M (1986). The Hamilton Depression Scale. In Assessment of Depression (ed. N. Sartorius and T. A. Ban), pp. 143-152. Springer: Berlin.
23. Hamilton M (1987). Assessment of psychopathology. In Human Psychopharmacology. Measures and Methods (ed. I. Hindmarch and P. D. Stonier), pp. 1-18. Wiley: Chichester.
24. Hays RD, Hadorn D (1992). Responsiveness to change: an aspect of validity, not a separate dimension. Quality of Life Research 1, 73-75.
25. Hays RD, Morales LS, Reise SP (2000). Item response theory and health outcome measurement in the 21st century. Medical Care 38 (Suppl. 2), 28-42.
26. Hedges LV, Olkin I (1985). Statistical Methods for Meta-analysis. Academic Press: Orlando.
27. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. Public Library of Science Medicine 5, 260-268.
28. Kuhn R (1958). The treatment of depressive states with G 22355 (imipramine hydrochloride). American Journal of Psychiatry 115, 459-464.
29. Kuhn R (1970). The imipramine story. In Discoveries in biological psychiatry (ed. F. J. Ayd and B. Blackwell), pp. 205-217. Lippincott: Philadelphia.
30. Lauritzen L, Odgaard K, Clemmesen L, Lunde M, Ô hrström J, Black C, Bech P (1996). Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy. Acta Psychiatrica Scandinavica 94 241-251.
31. Leber P (1996). The role of the regulator in the evaluation of the acceptability of new drug products. In Psychotropic Drug Development (ed. D. Healy and D. P. Doogan), pp. 69-77. Chapman & Hall Medical: London.
32. Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgren K (1987). The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica (Suppl.) 334, 1-100.
33. Mayer DY (1975). Psychotropic drugs and the 'anti-depressed' personality. British Journal of Medical Psychology 48, 349-357.
34. Montgomery SA, Asberg M. (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382-389.
35. NICE (2004). (http://www.nice.org.uk/nicemedia/pdf/ CG23fullguideline. pdf), p. 41. National Institute for Health and Clinical Excellence.
36. Øhrberg S, Christiansen PE, Severin B (1992). Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice. Acta Psychiatrica Scandinavica 86, 437-444.
37. Overall JE (1962). The dimensions of manifest depression. Psychiatric Research 1, 239-245.
38. Parker G (2009). Antidepressants on trial: how valid is the evidence. British Journal of Psychiatry 194, 1-3.
39. Porter AMW (1970). Depressive illness in a general practice. A demographic study and a controlled trial of imipramine. British Medical Journal 1, 773-778.
40. Pinder RM, Zivkov M (1998). On demonstrating the correct dose for new antidepressants. In Clinical Pharmacology in Psychiatry: Finding the Right Dose of Psychotropic Drugs (ed. L. P. Balant, J. Benitez, S. G. Dahl, L. F. Gram, R. M. Pinder and W. Z. Potter), pp. 31-42. European Commission: Brussels.
41. Rasch G (1980). Probalistic Models for Some Intelligence and Attainment Tests. University of Chicago Press: Chicago.
42. Rasmussen A, Lunde M, Poulsen DL, Sørensen K, Qvitzau S, Bech P (2003). A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics 44, 216-221.
43. Riskind JH, Beck AT, Brown G, Steer RA (1987). Taking the measure of anxiety and depression. Validity of the reconstructed Hamilton Scales. Journal of Nervous and Mental Disorders 175, 474-479.
44. Robinson RG, Jorge RE (2009). Prevention of first-episode depression: progress and potential. British Journal of Psychiatry 194, 296-297.
45. Ruhé HG, Dekker JJ, Peen J, Holmen R, de Jonghe F (2005). Clinical use of the Hamilton Depression Rating scale: is increased efficiency possible? A post hoc comparison of Hamilton Depression Rating Scale, Maier and Bech subscales, Clinical Global Impression, and Symptom Checklist-90 scores. Comprehensive Psychiatry 46, 417-427.
46. Rush AJ, Beck AT, Kovacs M, Hollon S (1977). Comparative efficacy of cognitive therapy and imipramine in the treatment of depressed outpatients. Cognitive Therapy and Research 1, 17-37.
47. Ryle G (1949). The Concept of Mind. Hutchinson: London.
48. Santen G, Gomeni R, Danhof M, Pasqua OD (2008). Sensitivity of the Hamilton Depression Scale to response and its consequence for the assessment of efficacy. Psychiatric Research 42, 100-109.
49. Smith A, Tranganzo E, Harrison G (1969). Studies on the effectiveness of antidepressant drugs. Psychopharmacology Bulletin (Suppl.), 1-53.
50. Steinmeyer EM, Möller H-J (1992). Facet theoretic analysis of the Hamilton-D scale. Journal of Affective Disorders 25, 53-62.
51. Turner EH (2008). Efficacy of antidepressants. British Medical Journal 336, 516-517.
52. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal B (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 358, 252-260
53. Young LPH, Plosker GL (2008). Desvenlafaxine extended release. CNS Drugs 22, 1061-1069.